Phase 3 N=40 Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)
Primary Immunodeficiency (PID)
Primary: Total Serum IgG Trough Levels — 7.97 g/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=12,537 The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)
Diabetes Mellitus, Non-Insulin-Dependent
Primary: Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI) or Nonfatal Stroke — 1041; 1013; 484; 476 participants — p=0.6273
Phase 3 N=590 Prevention of Recurrence of Diverticulitis
Diverticulitis
Primary: Percent of Subjects Without Recurrence of Diverticulitis — 62.2; 62.9; 52.7; 64.6 percentage of subjects — p=0.047
Phase 3 N=21 Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)
Primary Immune Deficiency
Primary: Annualized Rate of Serious Bacterial Infection (Intention-to-Treat Population) — 0.06 infections per subject year
Phase 3 N=49 Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy
Primary Immune Deficiency
Primary: Annualized Rate of Clinically Documented Serious Bacterial Infections (SBIs) (MITT Population) — 0.00 SBIs per subject year
Phase 3 N=473 Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients
Parkinson Disease
Primary: Change From Baseline in Unified Parkinsons Disease Rating Scale (UPDRS) Parts II+III Score at Week 18 — -13.807; -13.047 Units on a scale — p=<0.0001
Phase 3 N=3,449 Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study
Venous Thrombosis
Primary: Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal…
Phase 3 N=101 Exercise to Treat Depression in Individuals With Coronary Heart Disease
Depression · Heart Diseases
Primary: Hamilton Depression Rating Scale — -7.5; -6.1; -4.5 Raw changes in Ham-D scores
Phase 3 N=4,833 Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study
Pulmonary Embolism
Primary: Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal…
Phase 3 N=574 Comprehensive Add on Study in Japan
Diabetes Mellitus, Type 2
Primary: Incidence of Adverse Events (AEs) — 69; 55; 62; 114 Patients
Phase 3 N=339 A Study to Assess the Long-term Safety of QVA149
Chronic Obstructive Pulmonary Disease
Primary: Number of Participants With Adverse Events, Serious Adverse Events or Death — 130; 64; 37; 12 participants
Phase 3 N=109 SANTE - Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy
Epilepsy
Primary: Primary Analysis: Change in Seizure Rate — -40.4; -14.5 Percentage change from baseline — p=0.0017
Phase 3 N=1,097 A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)
Age-related Macular Degeneration
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 — 10.1; 9.2; 8.2; 8.6 Letters
Phase 3 N=3,647 Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects
Pandemic Influenza Disease
Primary: Number of Subjects With at Least One Reactogenicity Sign After Two Doses of the Adjuvanted Pandemic Influenza Vaccine. — 1755; 502; 237; 78 Participants
Phase 3 N=163 Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients
Chronic Obstructive Pulmonary Disease
Primary: Number of Participants With Adverse Events, Serious Adverse Events or Death — 102; 33; 16; 6 participants